Co-Diagnostics Analyst Ratings
Co-Diagnostics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 72.41% | HC Wainwright & Co. | $3 → $2 | Maintains | Neutral |
| 05/15/2023 | 158.62% | HC Wainwright & Co. | → $3 | Reiterates | Neutral → Neutral |
| 03/20/2023 | 158.62% | HC Wainwright & Co. | $6 → $3 | Downgrades | Buy → Neutral |
| 02/23/2023 | 417.24% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 11/14/2022 | 417.24% | HC Wainwright & Co. | $9 → $6 | Maintains | Buy |
| 08/15/2022 | 675.86% | HC Wainwright & Co. | $12 → $9 | Maintains | Buy |
| 08/12/2022 | 331.03% | Sidoti & Co. | → $5 | Downgrades | Buy → Neutral |
| 05/16/2022 | 934.48% | HC Wainwright & Co. | $15 → $12 | Maintains | Buy |
| 11/12/2021 | 1193.1% | HC Wainwright & Co. | $16 → $15 | Maintains | Buy |
| 03/29/2021 | — | Maxim Group | Downgrades | Buy → Hold | |
| 03/26/2021 | 1279.31% | HC Wainwright & Co. | $30 → $16 | Maintains | Buy |
| 12/15/2020 | 2486.21% | HC Wainwright & Co. | $29 → $30 | Maintains | Buy |
| 11/17/2020 | 2400% | HC Wainwright & Co. | $33 → $29 | Maintains | Buy |
| 08/14/2020 | 2744.83% | HC Wainwright & Co. | $35 → $33 | Maintains | Buy |
| 05/20/2020 | 2486.21% | Maxim Group | → $30 | Upgrades | Hold → Buy |
| 05/18/2020 | 2917.24% | HC Wainwright & Co. | $20 → $35 | Reiterates | → Buy |
| 03/03/2020 | — | Maxim Group | Downgrades | Buy → Hold | |
| 02/24/2020 | 244.83% | HC Wainwright & Co. | $2 → $4 | Maintains | Buy |
| 04/09/2019 | 72.41% | Maxim Group | → $2 | Initiates Coverage On | → Buy |
| 03/11/2019 | 72.41% | HC Wainwright & Co. | → $2 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月14日 | 72.41% | HC Wainwright公司 | $3→$2 | 維護 | 中性 |
| 2023年05月15日 | 158.62% | HC Wainwright公司 | →$3 | 重申 | 中性→中性 |
| 03/20/2023 | 158.62% | HC Wainwright公司 | $6→$3 | 評級下調 | 購買→中性 |
| 02/23/2023 | 417.24% | HC Wainwright公司 | →$6 | 重申 | →購買 |
| 2022年11月14日 | 417.24% | HC Wainwright公司 | $9→$6 | 維護 | 買 |
| 2022年08月15日 | 675.86% | HC Wainwright公司 | $12→$9 | 維護 | 買 |
| 2022年08月12日 | 331.03% | 西多蒂公司 | →$5 | 評級下調 | 購買→中性 |
| 05/16/2022 | 934.48% | HC Wainwright公司 | $15→$12 | 維護 | 買 |
| 2021年11月12日 | 1193.1% | HC Wainwright公司 | $16→$15 | 維護 | 買 |
| 03/29/2021 | - | Maxim集團 | 評級下調 | 購買→Hold | |
| 03/26/2021 | 1279.31% | HC Wainwright公司 | $30→$16 | 維護 | 買 |
| 12/15/2020 | 2486.21% | HC Wainwright公司 | $29→$30 | 維護 | 買 |
| 11/17/2020 | 2400% | HC Wainwright公司 | $33→$29 | 維護 | 買 |
| 2020/08/14 | 2744.83% | HC Wainwright公司 | $35→$33 | 維護 | 買 |
| 05/20/2020 | 2486.21% | Maxim集團 | →$30 | 升級 | 持有→購買 |
| 05/18/2020 | 2917.24% | HC Wainwright公司 | $20→$35 | 重申 | →購買 |
| 03/03/2020 | - | Maxim集團 | 評級下調 | 購買→Hold | |
| 02/24/2020 | 244.83% | HC Wainwright公司 | $2→$4 | 維護 | 買 |
| 2019年09月04日 | 72.41% | Maxim集團 | →$2 | 開始承保 | →購買 |
| 2019年3月11日 | 72.41% | HC Wainwright公司 | →$2 | 開始承保 | →購買 |
What is the target price for Co-Diagnostics (CODX)?
聯合診斷(CODX)的目標價格是多少？
The latest price target for Co-Diagnostics (NASDAQ: CODX) was reported by HC Wainwright & Co. on August 14, 2023. The analyst firm set a price target for $2.00 expecting CODX to rise to within 12 months (a possible 72.41% upside). 6 analyst firms have reported ratings in the last year.
聯合診斷公司(納斯達克代碼：CODX)的最新目標價是由HC Wainwright&Co.於2023年8月14日報告的。這家分析公司將目標價定為2.00美元，預計CODX將在12個月內上漲至72.41%。6家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Co-Diagnostics (CODX)?
聯合診斷(CODX)的最新分析師評級是多少？
The latest analyst rating for Co-Diagnostics (NASDAQ: CODX) was provided by HC Wainwright & Co., and Co-Diagnostics maintained their neutral rating.
聯合診斷公司(納斯達克代碼：CODX)的最新分析師評級由HC Wainwright&Co.提供，聯合診斷公司維持中性評級。
When is the next analyst rating going to be posted or updated for Co-Diagnostics (CODX)?
聯合診斷(CODX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Co-Diagnostics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Co-Diagnostics was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Co-Diagnostics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Co-Diagnostics的上一次評級是在2023年8月14日提交的，因此您應該預計下一次評級將在2024年8月14日左右提供。
Is the Analyst Rating Co-Diagnostics (CODX) correct?
分析師評級聯合診斷(CODX)是否正確？
While ratings are subjective and will change, the latest Co-Diagnostics (CODX) rating was a maintained with a price target of $3.00 to $2.00. The current price Co-Diagnostics (CODX) is trading at is $1.16, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的聯合診斷(CODX)評級保持不變，目標價在3.00美元至2.00美元之間。目前聯合診斷公司(CODX)的交易價格為1.16美元，超出了分析師的預測區間。